Albany Molecular Research Inc. (AMRI) is seeking a partner to progress development of its 5-HT3 partial agonist program. AMRI’s advanced compounds are mechanistically differentiated from current medications targeting this receptor.
Partial activation of the 5-HT3 receptor is an emerging strategy for the treatment of IBS. AMRI has targeted 5-HT3 receptor partial agonists that will moderate but not completely block the function of the 5-HT3 receptor. This profile is expected to overcome well-known deficiencies of existing full receptor antagonists.
AMRI has identified its first preclinical candidate, ALB-137391(a) and back-up candidates that are available for partnering. For additional information, view poster >>
ALB-137391(a), a selective, low intrinsic activity 5-HT3 receptor partial agonist, has been identified as a novel preclinical candidate for irritable bowel syndrome. ALB-137391(a) exhibits potent oral activity in preclinical models with an excellent preclinical drug safety profile.
AMRI has already initiated non-clinical safety pharmacology and toxicity studies for ALB-137391(a) and has GMP material available to support the subsequent human clinical studies. For more information, download the following poster pertaining to our 5-HT3 program: